126 related articles for article (PubMed ID: 28785028)
1. PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma.
Otani Y; Ishida J; Kurozumi K; Oka T; Shimizu T; Tomita Y; Hattori Y; Uneda A; Matsumoto Y; Michiue H; Tomida S; Matsubara T; Ichikawa T; Date I
Sci Rep; 2017 Aug; 7(1):7391. PubMed ID: 28785028
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of extracellular matrix protein CCN1 as a prognostic factor for glioblastoma.
Ishida J; Kurozumi K; Ichikawa T; Otani Y; Onishi M; Fujii K; Shimazu Y; Oka T; Shimizu T; Date I
Brain Tumor Pathol; 2015 Oct; 32(4):245-52. PubMed ID: 26201842
[TBL] [Abstract][Full Text] [Related]
3. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance.
Thorne AH; Meisen WH; Russell L; Yoo JY; Bolyard CM; Lathia JD; Rich J; Puduvalli VK; Mao H; Yu J; Caligiuri MA; Tridandapani S; Kaur B
Mol Ther; 2014 Sep; 22(9):1678-87. PubMed ID: 24895995
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of G-protein-coupled receptors 65 in glioblastoma predicts poor patient prognosis.
Wang HX; Chen YH; Zhou JX; Hu XY; Tan C; Yan Y; Huang QL; Shen JY; Xu HC; Li F; Gong ZY; Xu T; Chen JX
Clin Neurol Neurosurg; 2018 Jan; 164():132-137. PubMed ID: 29223793
[TBL] [Abstract][Full Text] [Related]
5. Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration.
Uneda A; Kurozumi K; Fujimura A; Fujii K; Ishida J; Shimazu Y; Otani Y; Tomita Y; Hattori Y; Matsumoto Y; Tsuboi N; Makino K; Hirano S; Kamiya A; Date I
Acta Neuropathol Commun; 2021 Feb; 9(1):29. PubMed ID: 33618763
[TBL] [Abstract][Full Text] [Related]
6. PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways.
Mu N; Gu J; Liu N; Xue X; Shu Z; Zhang K; Huang T; Chu C; Zhang W; Gong L; Zhao H; Jia B; Gao D; Shang L; Zhang W; Guo Q
Theranostics; 2018; 8(6):1527-1539. PubMed ID: 29556339
[No Abstract] [Full Text] [Related]
7. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
8. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.
Jungk C; Mock A; Exner J; Geisenberger C; Warta R; Capper D; Abdollahi A; Friauf S; Lahrmann B; Grabe N; Beckhove P; von Deimling A; Unterberg A; Herold-Mende C
BMC Med; 2016 Oct; 14(1):170. PubMed ID: 27782828
[TBL] [Abstract][Full Text] [Related]
9. Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.
Tabone T; Abuhusain HJ; Nowak AK; ; Erber WN; McDonald KL
J Clin Pathol; 2014 Jul; 67(7):550-5. PubMed ID: 24695838
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis.
Qian Z; Ren L; Wu D; Yang X; Zhou Z; Nie Q; Jiang G; Xue S; Weng W; Qiu Y; Lin Y
Int J Cancer; 2017 Jun; 140(12):2792-2804. PubMed ID: 28295288
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.
Michaelsen SR; Urup T; Olsen LR; Broholm H; Lassen U; Poulsen HS
J Neurooncol; 2018 May; 137(3):533-542. PubMed ID: 29305787
[TBL] [Abstract][Full Text] [Related]
12. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas.
Lee D; Suh YL; Park TI; Do IG; Seol HJ; Nam DH; Kim ST
J Surg Oncol; 2013 May; 107(6):646-52. PubMed ID: 22926763
[TBL] [Abstract][Full Text] [Related]
14. High expression of PCBP2 is associated with progression and poor prognosis in patients with glioblastoma.
Luo K; Zhuang K
Biomed Pharmacother; 2017 Oct; 94():659-665. PubMed ID: 28787701
[TBL] [Abstract][Full Text] [Related]
15. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
16. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
[TBL] [Abstract][Full Text] [Related]
17. ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: A clinicopathologic study.
Romano FJ; Guadagno E; Solari D; Borrelli G; Pignatiello S; Cappabianca P; Del Basso De Caro M
J Cell Biochem; 2018 Jun; 119(6):4867-4877. PubMed ID: 29369420
[TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
19. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
20. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
